Details

Autor(en) / Beteiligte

• Laish, Ido
• Schechter, Menachem
• Dancour, Alain
• Lieberman, Sari
• Levi, Zohar
• Goldberg, Yael
• Kedar, Inbal
• Hasnis, Erez
• Half, Elizabeth
• Levi, Gili Reznick
• Katz, Lior
• Vainer, Elez D.
• Genzel, Dor
• Aharoni, Maya
• Chen‐Shtoyerman, Rakefet
• Abu‐Freha, Naim
• Raitses‐Gurevich, Maria
• Golan, Talia
• Bernstein‐Molho, Rinat
• Ben Yehoyada, Merav
• Gluck, Nathan
• Rosner, Guy

Titel

The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants

Ist Teil von

• Cancer, 2024-01, Vol.130 (2), p.256-266

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Surveillance of high‐risk individuals for pancreatic ductal adenocarcinoma (PDAC) is recommended. This study aimed to determine the prevalence and outcomes of PDAC and its precursor lesions in BRCA1/2 pathogenic variants (PVs) carriers undergoing pancreatic surveillance. Methods A retrospective multicenter cohort study of pancreatic surveillance outcomes in Israeli BRCA1/2 carriers preferably with a family history of PDAC. Results A total of 180 asymptomatic carriers participated in the screening programs, including 57 (31.7%) with BRCA1 PVs, 121 (67.2%) with BRCA2 PVs, and 12 (6.6%) with PVs in BRCA1/2 and other genes, for a median follow‐up period of 4 years. Ninety‐one individuals (50.5%) fulfilled the International Cancer of the Pancreas Screening (CAPS) criteria for surveillance whereas 116 (64.4%) fulfilled the American College of Gastroenterology (ACG) criteria. There were four cases of adenocarcinoma and four cases of grade 1‐neuroendocrine tumor (G1‐NET). All were BRCA2 carriers, and two had no family history of PDAC. Three cancer patients were at resectable stages (IA, IIA, IIB) whereas one had a stage IIIB tumor. Of the G1‐NET cases, one had surgery and the others were only followed. Success rate for detection of confined pancreatic carcinoma was thus 1.6% (three of 180) in the whole cohort, 1.6% (two of 116) among individuals who fulfilled ACG criteria and 2.2% (two of 91) in those fulfilling CAPS criteria for surveillance. Conclusions Despite the low detection rate of PDAC and its' high‐risk neoplastic precursor lesions among BRCA1/2 carriers undergoing pancreatic surveillance, 75% of cancer cases were detected at a resectable stage. In a surveillance program of 180 BRCA1/2 carriers for pancreatic cancer, four cases of cancer were detected. Despite this overall low detection rate (2.2%), 75% of them were successfully detected at relatively early, resectable stage.